Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Company Overview - Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases [3] - The company is currently developing TH103, a novel anti-VEGF investigational therapy designed to improve VEGF inhibition and retention in the retina [3] Product Development - TH103 is a fully humanized, recombinant fusion protein acting as a decoy receptor against VEGF, developed by Dr. Napoleone Ferrara [3] - TH103 is undergoing a Phase 1 clinical trial for the treatment of neovascular Age-related Macular Degeneration (nAMD) and has plans for further development in conditions like Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO) [3] Upcoming Events - Kalaris Therapeutics will present at the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference on June 5th, 2025, featuring a Q&A session [1][4] - A replay of the event will be available on Kalaris Therapeutics' Investor Relations webpage following the presentation [2]